000823869 001__ 823869
000823869 005__ 20210129224857.0
000823869 0247_ $$2doi$$a10.1002/cbic.201500623
000823869 0247_ $$2ISSN$$a1439-4227
000823869 0247_ $$2ISSN$$a1439-7633
000823869 0247_ $$2WOS$$aWOS:000375124500003
000823869 0247_ $$2altmetric$$aaltmetric:5973924
000823869 0247_ $$2pmid$$apmid:26910367
000823869 037__ $$aFZJ-2016-06509
000823869 082__ $$a540
000823869 1001_ $$0P:(DE-Juel1)162443$$aNagel-Steger, Luitgard$$b0$$ufzj
000823869 245__ $$aAn Account of Amyloid Oligomers: Facts and Figures Obtained from Experiments and Simulations
000823869 260__ $$aWeinheim$$bWiley-VCH$$c2016
000823869 3367_ $$2DRIVER$$aarticle
000823869 3367_ $$2DataCite$$aOutput Types/Journal article
000823869 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1479800458_4739
000823869 3367_ $$2BibTeX$$aARTICLE
000823869 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000823869 3367_ $$00$$2EndNote$$aJournal Article
000823869 520__ $$aThe deposition of amyloid in brain tissue in the context of neurodegenerative diseases involves the formation of intermediate species—termed oligomers—of lower molecular mass and with structures that deviate from those of mature amyloid fibrils. Because these oligomers are thought to be primarily responsible for the subsequent disease pathogenesis, the elucidation of their structure is of enormous interest. Nevertheless, because of the high aggregation propensity and the polydispersity of oligomeric species formed by the proteins or peptides in question, the preparation of appropriate samples for high-resolution structural methods has proven to be rather difficult. This is why theoretical approaches have been of particular importance in gaining insights into possible oligomeric structures for some time. Only recently has it been possible to achieve some progress with regard to the experimentally based structural characterization of defined oligomeric species. Here we discuss how theory and experiment are used to determine oligomer structures and what can be done to improve the integration of the two disciplines.
000823869 536__ $$0G:(DE-HGF)POF3-553$$a553 - Physical Basis of Diseases (POF3-553)$$cPOF3-553$$fPOF III$$x0
000823869 588__ $$aDataset connected to CrossRef
000823869 7001_ $$0P:(DE-HGF)0$$aOwen, Michael C.$$b1
000823869 7001_ $$00000-0002-8734-7765$$aStrodel, Birgit$$b2$$eCorresponding author
000823869 773__ $$0PERI:(DE-600)2020469-3$$a10.1002/cbic.201500623$$gVol. 17, no. 8, p. 657 - 676$$n8$$p657 - 676$$tChemBioChem$$v17$$x1439-4227$$y2016
000823869 8564_ $$uhttps://juser.fz-juelich.de/record/823869/files/An%20Account%20of%20Amyloid%20Oligomers%3A%20Facts%20and%20Figures%20Obtained%20from%20Experiments%20and%20Simulations_2016.pdf$$yRestricted
000823869 8564_ $$uhttps://juser.fz-juelich.de/record/823869/files/An%20Account%20of%20Amyloid%20Oligomers%3A%20Facts%20and%20Figures%20Obtained%20from%20Experiments%20and%20Simulations_2016.gif?subformat=icon$$xicon$$yRestricted
000823869 8564_ $$uhttps://juser.fz-juelich.de/record/823869/files/An%20Account%20of%20Amyloid%20Oligomers%3A%20Facts%20and%20Figures%20Obtained%20from%20Experiments%20and%20Simulations_2016.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
000823869 8564_ $$uhttps://juser.fz-juelich.de/record/823869/files/An%20Account%20of%20Amyloid%20Oligomers%3A%20Facts%20and%20Figures%20Obtained%20from%20Experiments%20and%20Simulations_2016.jpg?subformat=icon-180$$xicon-180$$yRestricted
000823869 8564_ $$uhttps://juser.fz-juelich.de/record/823869/files/An%20Account%20of%20Amyloid%20Oligomers%3A%20Facts%20and%20Figures%20Obtained%20from%20Experiments%20and%20Simulations_2016.jpg?subformat=icon-640$$xicon-640$$yRestricted
000823869 8564_ $$uhttps://juser.fz-juelich.de/record/823869/files/An%20Account%20of%20Amyloid%20Oligomers%3A%20Facts%20and%20Figures%20Obtained%20from%20Experiments%20and%20Simulations_2016.pdf?subformat=pdfa$$xpdfa$$yRestricted
000823869 909CO $$ooai:juser.fz-juelich.de:823869$$pVDB
000823869 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)162443$$aForschungszentrum Jülich$$b0$$kFZJ
000823869 9131_ $$0G:(DE-HGF)POF3-553$$1G:(DE-HGF)POF3-550$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lBioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences$$vPhysical Basis of Diseases$$x0
000823869 9141_ $$y2016
000823869 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000823869 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000823869 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCHEMBIOCHEM : 2015
000823869 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000823869 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000823869 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000823869 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000823869 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000823869 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000823869 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000823869 915__ $$0StatID:(DE-HGF)0550$$2StatID$$aNo Authors Fulltext
000823869 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000823869 920__ $$lyes
000823869 9201_ $$0I:(DE-Juel1)ICS-6-20110106$$kICS-6$$lStrukturbiochemie $$x0
000823869 980__ $$ajournal
000823869 980__ $$aVDB
000823869 980__ $$aUNRESTRICTED
000823869 980__ $$aI:(DE-Juel1)ICS-6-20110106
000823869 981__ $$aI:(DE-Juel1)IBI-7-20200312